Aromatase inhibitors and tamoxifen were demonstrated to reduce recurrence rates in ER+ early breast cancer for 10 and 5 years, respectively, and reduce breast cancer mortality [207]. This evidence concerns the gene CYP19A1 and breast carcinoma.